



Australian Government

Department of Health

Therapeutic Goods Administration

Consultation: Draft OTC medicine monograph: Laxatives: Docusate sodium and/or sennosides

Version 1.0, April 2015

TGA Health Safety
Regulation

About the Therapeutic Goods Administration (TGA)

- The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible for regulating medicines and medical devices.
- The TGA administers the *Therapeutic Goods Act 1989* (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary.
- The work of the TGA is based on applying scientific and clinical expertise to decision-making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices.
- The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action.
- To report a problem with a medicine or medical device, please see the information on the TGA website <<http://www.tga.gov.au>>.

Copyright

© Commonwealth of Australia 2015

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <tga.copyright@tga.gov.au>

Confidentiality

All submissions received will be placed on the TGA's Internet site, unless marked confidential. Any confidential material contained within your submission should be provided under a separate cover and clearly marked "IN CONFIDENCE". Reasons for a claim to confidentiality must be included in the space provided on the TGA submission coversheet. For submission made by individuals, all personal details, other than your name, will be removed from your submission before it is published on the TGA's Internet site. In addition, a list of parties making submissions will be published. If you do not wish to be identified with your submission you must specifically request this in the space provided on the submission coversheet.

Version history

Version	Description of change	Author	Effective date
V1.0	Original publication	OTC Medicines Evaluation/Medicines Authorisation Branch	30/04/2015

DRAFT

Contents

Introduction	5
Active substance	5
Dosage forms and strengths	5
Indications	6
Therapeutic indications for inclusion in the Australian Register of Therapeutic Goods	6
Docosate sodium	6
Sennosides A and B	6
Docosate sodium and sennosides	6
Label indications	6
Docosate sodium	6
Sennosides A and B	6
Docosate sodium and sennosides	6
Directions for use	6
Dosage	6
Advisory statements	7
For docosate sodium:	7
For sennosides:	7
For docosate sodium and sennosides:	8
Labelling	8
Quality requirements	8
Finished product specifications	8
Docosate sodium	8
Sennosides	9
Docosate sodium and sennosides	9

Introduction

This OTC Medicine Monograph outlines the requirements for Australian market authorisation of oral laxative medicines containing docusate sodium and/or sennosides, when applied for as an OTC New Medicine N2 application. Proposed medicines must comply with all aspects of the monograph relevant to their strength and dosage form to qualify for evaluation as an N2 application.

This monograph should be read in conjunction with the document [Requirements for OTC new medicine N2 applications](#).

Active substance

This monograph only applies to medicines containing docusate sodium (CAS no. 577-11-7) and/or Sennosides USP* (a partially purified complex containing not less than 60% Sennosides A and B) as active ingredients and excludes preparations containing any other salts or derivatives of these substances.

* The application form should specify both the quantity of Sennosides USP and the 'component' (or equivalent) content of Sennosides A and B.

Dosage forms and strengths

Acceptable dosage forms and strengths are shown in the table below.

Active substance/strength	Dosage forms (excludes modified release dosage forms)
Docusate sodium (as single active) 50 mg or 120 mg	Tablet (uncoated, film-coated), capsule
Sennosides A and B (as single active) 8 mg or 12 mg	Tablet (uncoated, film coated or chewable), capsule
Docusate sodium 50 mg and Sennosides A and B 8 mg (as fixed combination)	Tablet (uncoated, film-coated), capsule

Indications

Therapeutic indications for inclusion in the Australian Register of Therapeutic Goods

Docosate sodium

Faecal softener for relief of constipation.

Sennosides A and B

Stimulant laxative for relief of constipation.

Docosate sodium and sennosides

Faecal softener and stimulant laxative for relief of constipation.

Label indications

Docosate sodium

- Stool softener or softens the stools or stool softening laxative

Sennosides A and B

- For the relief (or treatment) of constipation (required)
- Laxative or stimulant laxative (also acceptable)

Docosate sodium and sennosides

- For the relief (or treatment) of constipation (required)
- References to stool softener and laxative or stimulant laxative as above (also acceptable)

Directions for use

Dosage

Dosage must be as shown in the table below.

Active ingredients and strength	Dosage
Docosate sodium 50mg	Adults and children 12 years and over: Two or three tablets/capsules twice daily, as necessary

Active ingredients and strength	Dosage
Docusate sodium 120mg	Adults and children 12 years and over: Two tablets/capsules once daily, as necessary
Sennosides A and B 8 mg	Adults and children over 12 years: Two to four tablets/capsules, as necessary
Sennosides A and B 12 mg	Adults and children over 12 years: One to three tablets/capsules, as necessary
Docusate sodium 50 mg and sennosides A and B 8 mg	Adults and children over 12 years: One or two tablets/capsules, as necessary. Increase up to 4 tablets/capsules if necessary.

Reference to taking the dose at bedtime is acceptable.

Advisory statements

The following statements, or words to the effect, are required:

For docusate sodium:

- Do not use in children under 12 years.
- Do not take with other medicines or liquid paraffin, unless advised by a doctor.
- Drink plenty of water.
- Increase fibre in diet except in cases of medication-induced constipation (e.g. with codeine);
- If symptoms persist, seek advice from a health care practitioner.
- Prolonged use is not recommended and may lead to dependence.

For sennosides:

- Do not use in children under 12 years.
- Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea.
- If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product.
- Drink plenty of water.
- Increase fibre in diet except in cases of medication-induced constipation (e.g. with codeine).
- If symptoms persist, seek advice from a health care practitioner.

- Prolonged use is not recommended and may lead to dependence or serious bowel problems.

For docusate sodium and sennosides:

Include all of the above statements for sennosides as well as the following, regarding docusate sodium:

- Do not take with other medicines or liquid paraffin, unless advised by a doctor.

Note: This monograph currently includes all required advisory statements for docusate sodium and sennosides, including those specified in the 'Australian regulatory guidelines for OTC medicines' (ARGOM) and the 'Required advisory statements for medicine labels' (RASML).

Labelling

Labelling must comply with all relevant Australian regulatory requirements, as detailed in the document [Requirements for OTC new medicine N2 applications](#), including all required warning statements.

Sennosides content should be expressed on labelling as 'Sennosides A and B'.

Quality requirements

In addition to the quality requirements outlined in the document [Requirements for OTC new medicine N2 applications](#), the specific requirements detailed below also apply.

Finished product specifications

In addition to other requirements specified in the document [Requirements for OTC new medicine N2 applications](#), the finished product specifications must comply, at a minimum, with the relevant set of requirements below.

The requirements below include relevant BP general monograph/USP General Chapter requirements and TGO78 requirements. References to pharmacopoeial monographs below refer to the **current** monograph at time of application.

As for all N2 applications, tests for identification, assay and dissolution must use either the relevant pharmacopoeial method validated for specificity and accuracy or an alternative equivalent or superior method validated fully as described in the ICH guideline, CPMP/ICH/381/95 *Note for Guidance on Validation of Analytical Procedures: Text and Methodology*.

Docusate sodium

The tests and limits of the USP monograph *Docusate Sodium Tablets* or BP monograph *Docusate Capsules*, as relevant, with the addition of:

- tablet/capsule appearance

- uniformity of dosage units (BP)¹
- microbiological quality, in compliance with TGO 77.

Sennosides

The tests and limits of the USP monograph *Sennosides Tablets*, with the addition of:

- tablet/capsule appearance
- microbiological quality, in compliance with TGO 77.

Docosate sodium and sennosides

The tests and limits of the USP monograph *Docosate Sodium Capsules* or BP monograph *Docosate Capsules*, as relevant, and the tests and limits of the USP monograph *Sennosides Tablets*, with the addition of:

- tablet/capsule appearance
- uniformity of dosage units (BP)¹
- microbiological quality, in compliance with TGO 77.

DRAFT

¹ Already captured in USP monographs. Included with reference to *Docosate Capsules BP* only.

Therapeutic Goods Administration

PO Box 100 Woden ACT 2606 Australia
Email: info@tga.gov.au Phone: 1800 020 653 Fax: 02 6232 8605
<http://www.tga.gov.au>

Reference/Publication #